- Previous Close
4.7100 - Open
4.8400 - Bid 4.1100 x 100
- Ask 4.7600 x 100
- Day's Range
4.1500 - 5.1300 - 52 Week Range
3.5200 - 20.9000 - Volume
267,699 - Avg. Volume
202,441 - Market Cap (intraday)
86.538M - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
-- - EPS (TTM)
-5.9500 - Earnings Date Mar 17, 2025 - Mar 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
29.71
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
adverum.comRecent News: ADVM
View More
Performance Overview: ADVM
Trailing total returns as of 3/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADVM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADVM
View MoreValuation Measures
Market Cap
97.98M
Enterprise Value
18.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
80.48
Price/Book (mrq)
0.68
Enterprise Value/Revenue
18.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.83%
Return on Equity (ttm)
-76.26%
Revenue (ttm)
1M
Net Income Avi to Common (ttm)
-94.11M
Diluted EPS (ttm)
-5.9500
Balance Sheet and Cash Flow
Total Cash (mrq)
153.24M
Total Debt/Equity (mrq)
50.84%
Levered Free Cash Flow (ttm)
-47.6M
Research Analysis: ADVM
View MoreCompany Insights: ADVM
ADVM does not have Company Insights
Research Reports: ADVM
View MoreDaily – Vickers Top Buyers & Sellers for 04/25/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/21/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/21/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.